Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Status:
Completed
Trial end date:
2010-04-23
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of
estrogen. It is not yet known which treatment regimen is more effective for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without
octreotide in treating postmenopausal women who have stage I, stage II, or stage III breast
cancer.